FREDERICK, Md.–(BUSINESS WIRE)– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced it submitted an … Read More

FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Alex … Read More

Funding to Advance Development of Drug Candidates Targeting Heparin-Induced Thrombocytopenia and Type 1 Diabetes FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics (“Veralox”), a preclinical stage company focused on accelerating the development of first-in-class … Read More

These four biotech startups reflect an ecosystem that is attracting founders, talent and capital. Frederick, Maryland continues to be a hotbed for biotech and a destination of choice for many … Read More

FREDERICK, Md., Aug. 31, 2018 /PRNewswire-PRWeb/ — Rare blood disorders are on VERALOX Therapeutics Inc.’s “hit” list. The company, a small molecule drug discovery and development firm based in the … Read More

Thrombocytopenia is a big word that can carry big consequences for those struggling with rare blood disorders, especially among those using heparin to treat and prevent blood clots. And for … Read More